Drug evaluation: Apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis

Current Opinion in Investigational Drugs

Volumn 7, Issue 11, 2006, Pages 1014-1019

  Thabet, Mohamed M ^a   Huizinga, Tom W J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APRATASTAT; BMS 561392; COLLAGENASE 3; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXAMIC ACID; INFLIXIMAB; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PLACEBO; SCIO 323; SCIO 469; TMI 1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; INJECTION SITE REACTION; INSOMNIA; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHADENOPATHY; MUSCULOSKELETAL DISEASE; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PNEUMONIA; PYELONEPHRITIS; RANDOMIZATION; REVIEW; RHEUMATOID ARTHRITIS; SINUSITIS; STRUCTURE ACTIVITY RELATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADAM PROTEINS; ANIMALS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; MATRIX METALLOPROTEINASE 13; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; MORPHOLINES; PATENTS; RATS; RATS, INBRED LEW; TREATMENT OUTCOME;

EID: 33751042569     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. 311600 Matrix metalloproteinases. Johnson LL, Dyer R, Hupe DJ CURR OPIN CHEM BIOL 1998 2 4 466-471
2. 362583 Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Dahlberg L, Billinghurst RC, Manner P, Nelson F, Webb G, Ionescu M, Reiner A, Tenzer M, Zukor D, Chen J, van Wart HE, Poole AR ARTHRITIS RHEUM 2000 43 3 673-682
3. 383734 Inflammation Research Association Tenth National Meeting (Part III) - overnight report - Hot Springs, VA, USA, 24-28 September 2000. Kelly D IDDB MEETING REPORT 2000 September 24-28
4. 384587 Design, synthesis and biological evaluation of a new class of TNF-α converting enzyme inhibitors for the treatment of rheumatoid arthritis. Levin JI, Albright JD, Ayra Kaloustian S, Barone D, Black RA, Ceretti DP, Chen J, Cheung K, Cole D, Cowling R, Davis J et al INFLAMM RES 2000 49 Suppl 2 S94
5. 397092 The discovery of anthranilic acid-based MMP Inhibitors. Part 1: SAR of the 3-position. Levin JI, Du MT, DiJoseph JF, Killar LM, Sung A, Walter T, Sharr MA, Roth CE, Moy FJ, Powers R, Jin G et al BIOORG MED CHEM LETT 2001 11 2 235-238
6. 407933 Scios: Case study in their p38 kinase inhibitor program. Schreiner G SMI CONF - ADV ANTI-ARTH AGENTS 2001 April 30 - May 01
7. 459255 Scios announces second quarter financial results and increases 2002 and peak sales forecasts for natrecor. Scios Inc PRESS RELEASE 2002 July 25
8. 466768 Benzodiazepine inhibitors of the MMPs and TACE. Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G et al BIOORG MED CHEM LETT 2002 20 12 2867-2870
9. 470328 American College of Rheumatology - 66th Annual Scientific Meeting, New Orleans, LA, USA. Slyvester B IDDB MEETING REPORT 2002 October 25-29
10. 478771 Development of a novel dual TACE/MMP inhibitor for treatment of RA. Zhang X, Aubin JE, Chiu B, Payne U, Inman RD AM COLL RHEUMATOL 2002 Abs 271
11. 495444 Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors. Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killer LM, Sung A, DiJoseph JF, Skotnicki JS et al BIOORG MED CHEM LETT 2003 13 8 1487-1490
12. 511530 Synthesis and structure-activity relationship of α-sulfonyl-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnick JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Cowling R J MED CHEM 2003 46 12 2361-2375
13. 512507 Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Xu ZB J MED CHEM 2003 46 12 2376-2396
14. 548273 Identification and characterization of 4-[I4-(2-butynyloxy)-phenyl]sufonyl]-N-hydroxy-2, 2-dimethyl(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-α-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, Brennan F, Cummons T, Clarke D, Vansell N, Nickerson-Nutter C et al J PHARMACOL EXP THER 2004 309 1 348-355
15. 558846 SCIO-469, a novel p38a MAP kinase inhibitor, provides efficacy in acute post-surgical dental pain. Tong SE, Daniels SE, Montano T, Chang S, Desjardins P CLIN PHARMACOL THER 2004 75 2 Abs PI-1
16. 558847 Pharmacokinetics (PK) and pharmacodynamics (PD) of SCIO-469, a p38 α MAP kinase inhibitor. Amakaye D, Tong S, Ward C, Beazley W CLIN PHARMACOL THER 2004 75 2 Abs PII-7
17. 572056 Bristol-Myers Squibb R and D Review. Bristol-Myers Squibb Co COMPANY PRESENTATION 2004 November 17
18. 580331 23rd Annual JP Morgan Healthcare Conference - Wyeth. Wyeth COMPANY PRESENTATION 2005 January 11
19. 605336 Johnson & Johnson pharmaceutical R&D review day. Johnson & Johnson COMPANY PRESENTATION 2005 May 26
20. 610382 EULAR 2005 - Annual European Rheumatology Congress, Vienna, Austria. Jorgensen C IDDB MEETING REPORT 2005 June 08-11
21. 619303 BMS-561392 - a TNFα convertase inhibitor for treating rheumatoid arthritis. Trzaskos JM INFLAMMATION RESEARCH 2005 54 Suppl 2 Abs 4007
22. 637271 A randomized, double-blind, placebo-controlled, sequential-dose study of the safety of apratastat (TMI-005), a novel oral dual inhibitor of TNF-α-converting enzyme/metalloproteinase, in patients with rheumatoid arthritis on a background of methotrexate. Fleischmann R, Kivitz AJ, Franklin C, Pavlik Gaylord S, Sridharan S, Kirsch TM ANN RHEUM DIS 2005 64 Suppl 3
23. 642059 Identification and characterization of apratastat (TMI-005), a potent, dual TACE/MMP inhibitor for the treatment of RA. Zhang Y, Xu J, Udata C, McDevitt J, Cummons T, Sun L, Zhu Y, Li G, Rao V, Wang Q, Gibbons J et al ANN RHEUM DIS 2005 64 Suppl 3 462-463
24. 642061 In vitro, ex vivo, in vivo inhibition of TNFα, a potent TNFα-converting enzyme (TACE) inhibitor for rheumatoid arthritis. Zhou H, Afsharvand M, Kotake A, Duan L, Zhang H, Noveck R, Raible D ANN RHEUM DIS 2005 64 Suppl 3 171
25. 642063 Efficacy of apratastat, a novel dual inhibitor of TNF-α converting enzyme/metalloproteinase, in experimental rodent models of rheumatoid arthritis. Hegen M, Zhang Y, Levin J, Xu J, Cummons T, Harding K, Albert L, Leathurby Y, Sheppard BJ, Leach MW ANN RHEUM DIS 2005 64 3 154
26. 689724 Acetylenic TACE Inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Levin JI, Chen JM, Laakso LM, Du M, Schmid J, Xu W, Cummons T, Xu J, Jin G, Barone D, Skotnicki JS BIOORG MED CHEM LETT 2006 16 6 1605-1609
27. 692936 Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-α-converting enzyme and matrix metalloproteinases despite their high structural similarity. Solomon A, Rosenblum G, Gonzales PE, Leonard JD, Mobashery S, Milla ME, Sagi I J BIOL CHEM 2004 279 30 31646-31654
28. 693124 Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J et al J CLIN INVEST 1997 99 7 1534-1545
29. 693127 Biochemical characterization of human collagenase-3. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G J BIOL CHEM 1996 271 3 1544-1550
30. 693129 Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE J CLIN INVEST 1996 97 3 761-768
31. 693130 Synthesis and structure-activity relationship of α-sulfonyl-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA et al MED CHEM 2003 46 12 2361-2375
32. 693166 Lack of efficacy with 3 oral dose levels of TMI-005 (apratastat), in subjects with active rheumatoid arthritis on a background of methotrexate - a phase 2 double-blind, placebo-controlled, parallel, randomized study. Fleischman R, Genovese M, Keystone EM, Pavelka L, Durez P, Pavlik-Gaylord S, Kirsch TM, Sridharan S ANNU EUR CONGR RHEUMATOL 2006 21-24 Abs FRI0172
33. 707181 Anti-TNFα therapy of rheumatoid arthritis: What can we learn about chronic disease? Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P, Williams R, Woody J, Maini RN NOVARTIS FOUND SYMP 2004 256 53-69
34. 707265 Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases. Taylor PC, Williams RO, Feldmann M CURR OPIN BIOTECHNOL 2004 15 6 557-563
35. 707524 TNFα as therapeutic target: New drugs, more applications. Reimold AM CURR DRUG TARGETS - INFLAMM ALLERGY 2002 1 4 377-392
36. 707776 Tumor necrosis factor-α converting enzyme. Black RA INT J BIOCHEM CELL BIOL 2002 341 1-5
37. 707958 The role of cytokines in osteoarthritis pathophysiology. Fernandes JC, Martel-Pelletier J, Pelletier JP BIORHEOLOGY 2002 39 1-2 237-246
38. 708262 Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: Preclinical and clinical studios. Feldmann M, Maini RN JOINT BONE SPINE 2002 69 1 12-18
39. 708856 Matrix metalloproteinases (MMPs) in health and disease: An overview. Malemud CJ FRONT BIOSCI 2006 11 1696-1701
40. 733001 Lack of efficacy of TMI-005 (apratastat) in patients with active RA on a background of methotrexate. Gourley IS, O'Toole M, Kirsch T, Gaylord S, Fatenejad A INFLAMM RES 2006 55 Suppl 5 Abs SA43